Skip to content

Study · In vitro (cells) · 2009

2 results

IL1beta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease.

Kidd M, Gustafsson BI, Drozdov I, Modlin IM

Neurogastroenterology and motility25 Oct 2008Cited by 109 (Europe PMC)

PMID19019013 (opens in a new tab)PMCIDPMC4040949 (opens in a new tab)DOI10.1111/j.1365-2982.2008.01210.x (opens in a new tab)PepBankPUB-19019013
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In isolated Crohn's intestinal enterochromaffin cells, lanreotide inhibited IL1beta-stimulated secretion with IC50 0.61 nmol L(-1).

    In plain wordsIn cells from Crohn's intestinal tissue, lanreotide inhibited stimulated serotonin release.

    Peptide
    Lanreotide
    Outcome
    DecreaseIL1beta-stimulated serotonin secretion in Crohn's cells
    Study

    humann = 6

    Isolated intestinal enterochromaffin cells
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    IC50
    0.61 nmol L(-1)
    Crohn's EC cells

    Source sentences

    Summary
    The somatostatin analogue, lanreotide inhibited IL1beta-stimulated secretion in Crohn's (IC(50) = 0.61 nmol L(-1)) and normal EC cells (IC(50) = 1.8 nmol L(-1)).
    2 context sentences
    Summary · context
    Pure (>98%) human intestinal EC cells were isolated by fluorescent activated cell sorting from preparations of normal (n = 5) and Crohn's colitis (n = 6) mucosa.
    Summary · context
    5HT release was measured (ELISA), and NFkappaB and ERK phosphorylation quantitated (ELISA) in response to IL1beta and LPS.
  2. 02LabIn vitro (cells)Activity measurement

    In isolated normal intestinal enterochromaffin cells, lanreotide inhibited IL1beta-stimulated secretion with IC50 1.8 nmol L(-1).

    In plain wordsIn cells from normal intestinal tissue, lanreotide inhibited stimulated serotonin release.

    Peptide
    Lanreotide
    Outcome
    DecreaseIL1beta-stimulated serotonin secretion in normal cells
    Study

    humann = 5

    Isolated intestinal enterochromaffin cells
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    IC50
    1.8 nmol L(-1)
    normal EC cells

    Source sentences

    Summary
    The somatostatin analogue, lanreotide inhibited IL1beta-stimulated secretion in Crohn's (IC(50) = 0.61 nmol L(-1)) and normal EC cells (IC(50) = 1.8 nmol L(-1)).
    2 context sentences
    Summary · context
    Pure (>98%) human intestinal EC cells were isolated by fluorescent activated cell sorting from preparations of normal (n = 5) and Crohn's colitis (n = 6) mucosa.
    Summary · context
    5HT release was measured (ELISA), and NFkappaB and ERK phosphorylation quantitated (ELISA) in response to IL1beta and LPS.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.